EcoDrugPlus

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSCPOG00000008093
Gene Symbol: AXL
2 Cross references
198 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCPOG00000021487
Gene Symbol: BRAF
2 Cross references
220 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSCPOG00000024581
Gene Symbol: BCL2
2 Cross references
228 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSCPOG00000039098
Gene Symbol: BCL2L1
4 Cross references
289 Possible Orthologues:

Bcl2 Like 2

Ensembl ID : ENSCPOG00000031913
Gene Symbol: BCL2L2
2 Cross references
64 Possible Orthologues:

Bcl2 Related Protein A1

Ensembl ID : ENSCPOG00000033645
Gene Symbol: BCL2A1
2 Cross references
133 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSCPOG00000021817
Gene Symbol: BCR
2 Cross references
286 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSCPOG00000000549
Gene Symbol: BTK
4 Cross references
206 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSCPOG00000035503
Gene Symbol: CCR4
3 Cross references
113 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSCPOG00000027230
Gene Symbol: CCR9
2 Cross references
265 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSCPOG00000037921
Gene Symbol: CXCL8
2 Cross references
179 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSCPOG00000021600
Gene Symbol: CXCR1
3 Cross references
230 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).